YAO Yao, ZHANG Xiping, GE Renjie, et al. Electroacupuncture for the prevention of chemotherapy-induced peripheral neuropathy: a randomized controlled trial[J]. Chinese Acupuncture & Moxibustion, 2024, 44(12): 1388-1394.
DOI:
YAO Yao, ZHANG Xiping, GE Renjie, et al. Electroacupuncture for the prevention of chemotherapy-induced peripheral neuropathy: a randomized controlled trial[J]. Chinese Acupuncture & Moxibustion, 2024, 44(12): 1388-1394.DOI: 10.13703/j.0255-2930.20240222-k0001.
Electroacupuncture for the prevention of chemotherapy-induced peripheral neuropathy: a randomized controlled trial
To investigate the clinical effect of electroacupuncture (EA) in preventing chemotherapy-induced peripheral neuropathy (CIPN)
. Methods
2
Fifty-two patients with breast cancer in the regimen of taxane-assisted/neoadjuvant chemotherapy
were randomly divided into an EA group (26 cases
3 cases dropped out) and a usual care (UC) group (26 cases
1 case dropped out). In the UC group
on the basis of standard chemotherapy regimen
the routine nursing was administered. In the EA group
on the intervention as the UC group
EA was added
the acupoints included Yintang (GV 24
+
)
Baxie (EX-UE 9
the second one)
Waiguan (TE 5)
Hegu (LI 4)
Quchi (LI 11)
Zusanli (ST 36)
Yinlingquan (SP 9)
Sanyinjiao (SP 6)
Taixi (KI 3)
Taichong (LR 3)
Xuanzhong (GB 39) and Bafeng (EX-LE 10
the fourth one). Electric stimulation was attached to Taichong (LR 3) and Sanyinjiao (SP 6) on the same side
with disperse-dense wave and the frequency of 2 Hz/10 Hz
for 30 min. EA started one day before the first cycle of chemotherapy
twice weekly in the first two weeks and once weekly in the rest weeks of chemo
therapy. The duration of the intervention with EA was 12 weeks. The incidence of CIPN was compared in week 24 of the trial between the two groups. At the baseline and in week 12 and 24 of the trial
the score of EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer on chemotherapy-induced peripheral nerve toxicity quality of life questionnaire 20)
the score of TCM syndrome scale and the score of EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer on quality of life scale) were observed in the two groups. At the baseline and in week 12 of the trial
the sensory nerve conduction velocity (SCV) and the motor nerve conduction velocity (MCV) was detected.
Results
2
In week 24 of the trial
the incidence of CIPN was 17.4% (4/23) in the EA group
lower than that (72.0%
18/25) in the UC group (
P
<
0.001). The incidence of high-grade CIPN was 0% (0/23) in the EA group
lower than that (28.0%
7/25) in the UC group (
P
<
0.05). In week 12 and 24 of the trial
the scores for the sensory nerve symptom of EORTC QLQ-CIPN20 and the total scores were higher when compared with the baseline in the UC group (
P
<
0.001
P
<
0.05
P
<
0.01). In week 24 of the trial
the score for the sensory nerve symptom of EORTC QLQ-CIPN20 in the EA group was lower than that of the UC group (
P
<
0.05). In week 12 of the trial
SCV of the right superficial peroneal nerve was reduced when compared with the baseline in the UC group (
P
<
0.05)
and SCV of the left median nerve and the right superficial peroneal nerve was higher in the EA group when compared with the UC group (
P
<
0.05
P
<
0.01). In week 12 and 24 of the trial
the scores for the secondary symptoms of TCM scale were decreased in the EA group compared with the baseline (
P
<
0.05)
and the scores for the primary and secondary symptoms
a
s well as the total scores of TCM scale were all higher than those of the baseline in the UC group (
P
<
0.01
P
<
0.001
P
<
0.05). In week 12 of the trial
the scores for the primary and secondary symptoms
as well as the total score of TCM scale in the EA group were lower than those of the UC group (
P
<
0.05
P
<
0.01). In week 24 of the trial
the score for the secondary symptoms and the total score of TCM scale in the EA group were lower than those of the UC group (
P
<
0.05). In week 12 of the trial
the scores for fatigue
pain
nausea and vomiting in EORTC QLQ-C30 were increased in comparison with the baseline in the UC group (
P
<
0.05
P
<
0.01); in week 24 of the trial
the score of the general health in EORTC QLQ-C30 was elevated when compared with the baseline in the EA group (
P
<
0.001)
and the scores for nausea and vomiting
loss of appetite were decreased in comparison with the baseline (
P
<
0.01). In week 12 of the trial
the score of the general health in EORTC QLQ-C30 in the EA group was higher compared with the UC group (
P
<
0.01)
and the scores for pain
nausea and vomiting were lower (
P
<
0.01
P
<
0.05). In week 24 of the trial
the score of the general health in EORTC QLQ-C30 was higher in the EA group compared with the UC group (
P
<
0.001)
and the score for loss of appetite was lower (
P
<
0.05).
Conclusion
2
Electroacupuncture reduces the incidence and severity of CIPN
ameliorates nerve conduction velocity and improves the quality of life of the patients.